Investors  Financial Outlook |
| |
| Financial Outlook |
 |
| Wanbury is set to grow in excess of 40% CAGR over the next 3-5 years considering: |
| |
 Strong API growth through existing products and new product introductions. |
| |
| Forward integration of APIs in formulations for sale of products in regulated markets. |
| |
| Increased CRAMS business from new & existing MNC clients. |
| |
| New branded product introductions in the Spanish markets including “First to Market” products, Value Added Branded Generics, Finished Dosage Combinations and In-Licensed patented products. |
| |
| New product launches and new divisions to be launched in India targeting the business to be in the top 20 companies over the next 3 years. |
| |
| Margin improvements on basis of various initiatives taken by the Company will give rise to enhanced earnings. |
| |
 |
| |
| |
